bioRxiv · 10.1101/2022.01.21.477288
Structural changes in the SARS-CoV-2 spike E406W mutant escaping a clinical monoclonal antibody cocktail
Abstract
The SARS-CoV-2 receptor-binding domain (RBD) E406W mutation abrogates neutralization mediated by the REGEN-CoV therapeutic monoclonal antibody (mAb) COVID-19 cocktail and the cilgavimab (AZD1061) mAb. Here, we show that this residue substitution remodels the ACE2-binding site allosterically, thereby dampening receptor recognition severely and altering the epitopes recognized by these three mAbs. Although vaccine-elicited neutralizing antibody titers are decreased similarly against the E406 mutant and the Delta or Epsilon variants, broadly neutralizing sarbecovirus mAbs, including a clinical mAb, inhibit the E406W spike mutant.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Addetia, A., Park, Y.-J., Starr, T., Greaney, A. J., Sprouse, K., Bowen, J. E., Tiles, S. W., Van Voorhis, W. C., Bloom, J. D., Corti, D., Walls, A. C., Veesler, D.. 2022-01-25. Structural changes in the SARS-CoV-2 spike E406W mutant escaping a clinical monoclonal antibody cocktail. https://doi.org/10.1101/2022.01.21.477288
Cite the original work for its findings. Save a collection to share your selection of sources.